Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319869999> ?p ?o ?g. }
- W4319869999 endingPage "114378" @default.
- W4319869999 startingPage "114378" @default.
- W4319869999 abstract "Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with high mortality and morbidity rate affecting both upper and lower motor neurons (MN). Muscle force reduction, behavioral change, pseudobulbar affect, and cognitive impairments are the most common clinical manifestations of ALS. The main physiopathology of ALS is still unclear, though several studies have identified that oxidative stress, proteinopathies, glutamate-related excitotoxicity, microglial activation, and neuroinflammation may be involved in the pathogenesis of ALS. From 1995 until October 2022, only Riluzole, Dextromethorphan Hydrobromide (DH) with Quinidine sulfate (Q), Edaravone, and Sodium phenylbutyrate with Taurursodiol (PB/TUDCO) have achieved FDA approval for ALS treatment. Despite the use of these four approved agents, the survival rate and quality of life of ALS patients are still low. Thus, finding novel treatments for ALS patients is an urgent requirement. Masitinib, a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. Masitinib downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces neuroprotection. Also, it was effective in phase 2/3 and 3 clinical trials (CTs) by increasing overall survival and delaying motor, bulbar, and respiratory function deterioration. This review describes the pathophysiology of ALS, focusing on Masitinib's mechanism of action and explaining why Masitinib could be a promising actor in the treatment of ALS patients. In addition, Masitinib CTs and other competitor drugs in phase 3 CTs have been discussed." @default.
- W4319869999 created "2023-02-11" @default.
- W4319869999 creator A5007424003 @default.
- W4319869999 creator A5039225576 @default.
- W4319869999 creator A5049081181 @default.
- W4319869999 creator A5062713059 @default.
- W4319869999 creator A5065615881 @default.
- W4319869999 creator A5070386123 @default.
- W4319869999 creator A5081273000 @default.
- W4319869999 creator A5090283271 @default.
- W4319869999 date "2023-04-01" @default.
- W4319869999 modified "2023-10-16" @default.
- W4319869999 title "Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series" @default.
- W4319869999 cites W1511318907 @default.
- W4319869999 cites W1556269168 @default.
- W4319869999 cites W1595801403 @default.
- W4319869999 cites W1903498519 @default.
- W4319869999 cites W1910228392 @default.
- W4319869999 cites W1928416749 @default.
- W4319869999 cites W1936774212 @default.
- W4319869999 cites W1959858628 @default.
- W4319869999 cites W1964309806 @default.
- W4319869999 cites W1967811268 @default.
- W4319869999 cites W1969223758 @default.
- W4319869999 cites W1971397654 @default.
- W4319869999 cites W1974540289 @default.
- W4319869999 cites W1980735023 @default.
- W4319869999 cites W1981530842 @default.
- W4319869999 cites W1982605324 @default.
- W4319869999 cites W1984538960 @default.
- W4319869999 cites W1987128031 @default.
- W4319869999 cites W1987376468 @default.
- W4319869999 cites W1987728948 @default.
- W4319869999 cites W1995222212 @default.
- W4319869999 cites W1995885857 @default.
- W4319869999 cites W2001037967 @default.
- W4319869999 cites W2003618511 @default.
- W4319869999 cites W2004628180 @default.
- W4319869999 cites W2006976627 @default.
- W4319869999 cites W2008271829 @default.
- W4319869999 cites W2008646706 @default.
- W4319869999 cites W2012261637 @default.
- W4319869999 cites W2016173304 @default.
- W4319869999 cites W2020061739 @default.
- W4319869999 cites W2027640796 @default.
- W4319869999 cites W2027999171 @default.
- W4319869999 cites W2032618470 @default.
- W4319869999 cites W2034454495 @default.
- W4319869999 cites W2040891140 @default.
- W4319869999 cites W2043200832 @default.
- W4319869999 cites W2046199264 @default.
- W4319869999 cites W2046645100 @default.
- W4319869999 cites W2048006381 @default.
- W4319869999 cites W2049919805 @default.
- W4319869999 cites W2051609624 @default.
- W4319869999 cites W2052176807 @default.
- W4319869999 cites W2055355861 @default.
- W4319869999 cites W2060230550 @default.
- W4319869999 cites W2067015275 @default.
- W4319869999 cites W2072562340 @default.
- W4319869999 cites W2075642592 @default.
- W4319869999 cites W2075959895 @default.
- W4319869999 cites W2077331144 @default.
- W4319869999 cites W2078154210 @default.
- W4319869999 cites W2079004973 @default.
- W4319869999 cites W2084586262 @default.
- W4319869999 cites W2085165928 @default.
- W4319869999 cites W2096386031 @default.
- W4319869999 cites W2096734155 @default.
- W4319869999 cites W2098225812 @default.
- W4319869999 cites W2104933407 @default.
- W4319869999 cites W2108381339 @default.
- W4319869999 cites W2108813293 @default.
- W4319869999 cites W2118084349 @default.
- W4319869999 cites W2119155057 @default.
- W4319869999 cites W2119656827 @default.
- W4319869999 cites W2128206335 @default.
- W4319869999 cites W2128768698 @default.
- W4319869999 cites W2140398365 @default.
- W4319869999 cites W2142064395 @default.
- W4319869999 cites W2144507462 @default.
- W4319869999 cites W2147180300 @default.
- W4319869999 cites W2152265294 @default.
- W4319869999 cites W2152769688 @default.
- W4319869999 cites W2154923417 @default.
- W4319869999 cites W2157921902 @default.
- W4319869999 cites W2167876561 @default.
- W4319869999 cites W2186898572 @default.
- W4319869999 cites W2252299061 @default.
- W4319869999 cites W2271187221 @default.
- W4319869999 cites W2276476697 @default.
- W4319869999 cites W2299148834 @default.
- W4319869999 cites W2314689571 @default.
- W4319869999 cites W2326891725 @default.
- W4319869999 cites W2330989831 @default.
- W4319869999 cites W2336601452 @default.
- W4319869999 cites W2336631222 @default.
- W4319869999 cites W2398585811 @default.